North America Male Infertility Market 2023-2030

North America Male Infertility Market 2023-2030

MARKET OUTLOOK

Triton Market Research’s report suggests that the male infertility market in North America is set to garner a compound annual growth rate of 4.41% in revenue over the forecasting years from 2023 to 2030. Canada and the United States are studied in the given region.

In the United States, the demand for assisted reproductive technology (ART) has risen. According to the CDC, around 326,468 ART cycles were conducted at 449 reporting clinics in 2020. Although ART is not yet widely opted for, its usage has gained traction as a viable solution to improve fertility rates. In 2020, approximately 2.0% of all babies born in the US resulted from ART. The number of ART cycles performed in 2021 increased by 19% from 2020. Hence, these factors are expected to further strengthen and promote the growth of the male infertility market in the United States.

Several factors, including a decline in fertility rates and a rise in health conditions, fuel the male infertility market in Canada. In this regard, market players are strategically developing solutions to address these issues, considering the growing burden of smoking, obesity, alcohol consumption, and sedentary lifestyles among the male population. This will further elevate the adoption of advanced male infertility treatments, thereby boosting the market’s development.

COMPETITIVE OUTLOOK

The notable companies in the male infertility market include Halotech DNA, EMD Serono Inc, Endo International Plc, Vitrolife, and Bayer AG.